84199-98-4

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 3-(3-PYRIDYL)PROPIONATE is used as an intermediate in the synthesis of various pharmaceuticals for its potential to contribute to the development of new drugs.
Used in Insecticide Production:
In the agricultural sector, METHYL 3-(3-PYRIDYL)PROPIONATE is used as a component in the production of insecticides, leveraging its properties to control and manage pest populations.
Used in Food and Beverage Industry:
METHYL 3-(3-PYRIDYL)PROPIONATE is used as a flavoring agent for its fruity aroma, enhancing the taste and appeal of various food and beverage products.
Used in Antifungal and Antibacterial Applications:
METHYL 3-(3-PYRIDYL)PROPIONATE has been studied for its potential pharmacological properties, including its ability to act as an antifungal and antibacterial agent, indicating its use in treatments and preventive measures against infections.

InChI:InChI=1/C9H11NO2/c1-12-9(11)5-4-8-3-2-6-10-7-8/h2-3,6-7H,4-5H2,1H3

Upstream product

• 67-56-1 methanol 
• 3724-19-4 3-pyridine propionic acid 
• 626-55-1 3-Bromopyridine 
• 292638-85-8 acrylic acid methyl ester 
• 6163-58-2 tris-(o-tolyl)phosphine 
• 75-05-8 acetonitrile 
• 19337-97-4 trans-3-(3-pyridyl)acrylic acid 
• 81124-48-3 methyl (E)-3-(3-pyridyl)acrylate 

Downstream Products

• 104642-48-0 C₉H₁₂N₂O₂*C₉H₁₂O₃S 
• 1026169-28-7 3-[2-Butyl-3-(2-chloro-benzyl)-3H-imidazol-4-yl]-3-hydroxy-2-pyridin-3-ylmethyl-propionic acid methyl ester 
• 2859-67-8 3-(3-pyridyl)propan-1-ol 
• 3724-19-4 3-pyridine propionic acid 
• 6293-56-7 3-pyridinylethanol 
• 279253-44-0 methyl 3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-3-hydroxy-2-(3-pyridylmethyl)propanate 
• 320608-52-4 C₈H₁₁N₃O 
• 200867-83-0 N-[4-(1-diphenylmethyl-piperidin-4-yl)-butyl]-3-(pyridin-3-yl)-propionamide 
• 944997-60-8 α-cyclohexyl-N-[1-[1-oxo-3-(3-pyridinyl)propyl]-4-piperidinyl]benzeneacetamide 
• 84199-99-5 3-(3-Pyridyl)propionsaeureamid 
• 1028285-62-2 (E)-3-[2-Butyl-3-(2-chloro-benzyl)-3H-imidazol-4-yl]-2-pyridin-3-ylmethyl-acrylic acid methyl ester 
• 143564-59-4 (E)-3-[2-Butyl-3-(2-chloro-benzyl)-3H-imidazol-4-yl]-2-pyridin-3-ylmethyl-acrylic acid 
• 109839-74-9 3-(3-bromopropyl)pyridine 
• 69603-49-2 3-(pyridin-3'-yl)propanethiol 

Relevant academic research and scientific papers

MICROBIOCIDAL QUINOLINE DIHYDRO-(THIAZINE)OXAZINE DERIVATIVES

Compounds of the formula (I): Formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.

A biocompatible alkene hydrogenation merges organic synthesis with microbial metabolism

Organic chemists and metabolic engineers use orthogonal technologies to construct essential small molecules such as pharmaceuticals and commodity chemicals. While chemists have leveraged the unique capabilities of biological catalysts for small-molecule production, metabolic engineers have not likewise integrated reactions from organic synthesis with the metabolism of living organisms. Reported herein is a method for alkene hydrogenation which utilizes a palladium catalyst and hydrogen gas generated directly by a living microorganism. This biocompatible transformation, which requires both catalyst and microbe, and can be used on a preparative scale, represents a new strategy for chemical synthesis that combines organic chemistry and metabolic engineering. Reduction to practice: A hydrogenation reaction has been developed that employs hydrogen generated in situ by a microorganism and a biocompatible palladium catalyst to reduce alkenes on a synthetically useful scale. This type of transformation, which directly combines tools from organic chemistry with the metabolism of a living organism for small-molecule production, represents a new strategy for chemical synthesis.

An investigation into the one-pot Heck olefination-hydrogenation reaction

Herein is described an operationally simple process concerning the observation that, following either inter-, or intramolecular Heck olefination, stirring of the so formed substituted alkenyl product under an atmosphere of hydrogen efficiently effects alkene hydrogenation. Overall this two-operation, one-pot "reductive Heck" sequence is notable since direct reductive Heck processes, using additives such as formate salts, are restricted to a limited range of substrates. In total 25 examples are reported (yields ranging from 0 to 95%), which were selected in order to probe the scope and limitations of this method. Finally, the utility of this sequence was demonstrated in a short synthesis of the calcimimetic agent, cinacalcet.

Discovery of new C3aR ligands. Part 2: Amino-piperidine derivatives

The synthesis and structure-activity relationships against the C3a receptor of a series of substituted aminopiperidine derivatives are reported. DMPK properties and functional activities of selected compounds are described. The compounds obtained are the first non-arginine ligands of C3aR.

Heterocyclic compounds as P2X7 ion channel blockers

The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: 1 wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer''s disease, etc.

Synthesis of N-glyoxyl prolyl and pipecolyl amides and thioesters and evaluation of their in vitro and in vivo nerve regenerative effects

The recent discovery that small molecule ligands for the peptidyl-prolyl isomerase (PPIase) FKBP12 possess powerful neuroprotective and neuroregenerative properties in vitro and in vivo suggests therapeutic utility for such compounds in neurodegenerative disease. The neurotrophic effects of these compounds are independent of the immunosuppressive pathways by which drugs such as FK506 and rapamycin operate. Previous work by ourselves and other groups exploring the structure-activity relationships (SAR) of small molecules that mimic only the FKBP binding domain portion of FK506 has focused on esters of proline and pipecolic acid. We have explored amide and thioester analogues of these earlier structures and found that they too are extremely potent in promoting recovery of lesioned dopaminergic pathways in a mouse model of Parkinson's disease. Several compounds were shown to be highly effective upon oral administration after lesioning of the dopaminergic pathway, providing further evidence of the potential clinical utility of a variety of structural classes of FKBP12 ligands.

Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents

Aryl-fused- and hetaryl-fused-2,4-diazepines of formula XXXVI, benzodiazocines of formula XXX, benzodiazepines of formula II STR1 δ-aminoamides of formula III and aryldimethanamines of formula XXXVII STR2 wherein A is an aryl or hetaryl ring; R1 is hydrogen, alkyl, aryl or hetaryl; R2 is hydrogen, alkyl, substituted alkyl, or aryl; R3 is alkyl, aryl, aralkyl or heteroatom substituted alkyl or aralkyl; R4 is hydrogen or alkyl; R5 is hydrogen, alkyl, aryl or hetaryl; R6 is hydrogen, alkyl, alkoxy, halogen or a fused benzene ring; R9 is hydrogen, alkyl, or substituted alkyl; and R10 is hydrogen, alkyl, or substituted alkyl. The invention further relates to processes for the preparation of, pharmaceutical compositions containing, and methods of treating cardiac arrhythmia with the compounds of formulas XXXVI, XXX, II, III, and XXXVII.